News >

Shah Highlights Shift Toward Earlier Use of IO and Targeted Therapy in Gastric/GEJ Cancer

Jessica Hergert
Published: Wednesday, Apr 01, 2020

Manish A. Shah, MD, the Bartlett Family Associate Professor of Gastrointestinal Oncology, associate professor of medicine at Weill Cornell Medical College, and associate attending physician at NewYork-Presbyterian Hospital

Manish A. Shah, MD

Despite multiple negative trials, the treatment paradigm of gastric/gastroesophageal junction (GEJ) cancer has shifted to include immunotherapy and targeted therapy, according to Manish A. Shah, MD. Moreover, these treatments, which may elicit significant responses for select patients, are moving from later lines of treatment to the first- and second-line settings.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication